Volume 130, Issue 7 p. 1028-1030
EDITORIAL

Innovations in group-based psilocybin-assisted therapy of major depression in patients with cancer

Johannes Thrul PhD

Corresponding Author

Johannes Thrul PhD

Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA

Centre for Alcohol Policy Research, La Trobe University, Melbourne, Victoria, Australia

Correspondence

Johannes Thrul, Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, 624 N Broadway, Room 887, Baltimore, MD 21205, USA.

Email: [email protected]

Search for more papers by this author
Zofia Kozak MD

Zofia Kozak MD

Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland, USA

Search for more papers by this author
Michael A. Carducci MD

Michael A. Carducci MD

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA

Search for more papers by this author
Albert Garcia-Romeu PhD

Albert Garcia-Romeu PhD

Department of Psychiatry and Behavioral Sciences, Center for Psychedelic and Consciousness Research, Johns Hopkins School of Medicine, Baltimore, Maryland, USA

Search for more papers by this author
David B. Yaden PhD

David B. Yaden PhD

Department of Psychiatry and Behavioral Sciences, Center for Psychedelic and Consciousness Research, Johns Hopkins School of Medicine, Baltimore, Maryland, USA

Search for more papers by this author
First published: 18 December 2023

Abstract

Several recent studies have investigated psilocybin as a novel therapeutic compound for the treatment of existential distress in patients with cancer, demonstrating persistent, positive effects on mood. This editorial discusses two articles in the current issue of Cancer that report findings of a group-based psilocybin-assisted intervention for treatment of depression in patients diagnosed with cancer.

CONFLICT OF INTEREST STATEMENT

Albert Garcia-Romeu is a scientific advisor to Innerwell. David B. Yaden reports grant funding from Sunstone Therapies. The other authors declare no conflicts of interest.

FUNDING INFORMATION

Johns Hopkins Center for Psychedelic and Consciousness Research.